Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan;74(1):142-150.
doi: 10.1002/acr.24421. Epub 2021 Dec 22.

Enhancing Patient Understanding of Medication Risks and Benefits

Susan J Blalock  1 , Elizabeth B Solow  2 , Valerie F Reyna  3 , Molly Keebler  4 , Delesha Carpenter  1 , Caprice Hunt  1 , Genevieve Hickey  1 , Jeffrey R Curtis  5 , Kimberlee O'Neill  1 , Sandra Bond Chapman  4
Affiliations
Randomized Controlled Trial

Enhancing Patient Understanding of Medication Risks and Benefits

Susan J Blalock et al. Arthritis Care Res (Hoboken). 2022 Jan.

Abstract

Objective: To evaluate the effectiveness of 2 interventions, including the DrugFactsBox format for presenting written medication information and the SMART (Strategic Memory Advanced Reasoning Training) program designed to enhance gist (i.e., "bottom-line" meaning) reasoning ability.

Methods: We used a 2 × 2 factorial research design. A total of 286 patients with rheumatoid arthritis were randomly assigned to 1 of 4 groups, including DrugFactsBox with the SMART program, DrugFactsBox without the SMART program, other consumer medication information (CMI) with the SMART program, and other CMI without the SMART program. Data were collected via telephone interviews and online questionnaires at 4 time points, including baseline and 6-week, 3-month, and 6-month time points following baseline. The primary outcome variable was informed decision-making, which was defined as making a value-consistent decision concerning use of disease-modifying antirheumatic drugs based on adequate knowledge.

Results: We found no main effects for the 2 interventions, either alone or in combination. However, there was a significant interaction between assignment to the SMART/no SMART groups and informed decision-making at baseline. Among participants in the SMART groups who did not meet the criteria for informed decision-making at baseline, 42.5% met the criteria at the 6-month follow-up, compared to 23.6% of participants in the no SMART groups (mean difference 18.9 [95% confidence interval 5.6, 32.2]; P = 0.007). This difference was driven by increased knowledge in the SMART groups. Among participants who met the criteria for informed decision-making at baseline, the difference between the SMART and no SMART groups was not statistically significant.

Conclusion: Participation in a theory-driven program to enhance gist reasoning may have a beneficial effect on informed decision-making among patients with inadequate knowledge concerning therapeutic options.

Trial registration: ClinicalTrials.gov NCT02820038.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Conceptual framework for gist reasoning training and written medication information.
See this image and copyright information in PMC

References

    1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39. - PMC - PubMed
    1. Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol 2014;66:775–82. - PMC - PubMed
    1. Fraenkel L, Cunningham M. High disease activity may not be sufficient to escalate care. Arthritis Care Res (Hoboken) 2014;66:197–203. - PMC - PubMed
    1. Van Hulst LT, Kievit W, van Bommel R, van Riel PL, Fraenkel L. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res (Hoboken) 2011;63:1407–14. - PMC - PubMed
    1. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease‐modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124–34. - PubMed

Publication types

Substances

Associated data

Grants and funding